US FDA Touts Benefits From Remote Assessments, Manufacturers Feel Burden – Trade Groups
Executive Summary
CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”